SCHEDULE: Armistice Capital Discloses 5.58% Stake in Voyager Therapeutics

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 3,436,000 shares, representing 5.58% of Voyager Therapeutics, Inc.'s common stock, as of June 30, 2026.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the 'Reporting Persons') have filed a Schedule 13G, indicating their beneficial ownership of 3,436,000 shares of Voyager Therapeutics, Inc. common stock.
• This holding represents 5.58% of the class of securities.
• The filing date for this event is June 30, 2026.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, may also be deemed to beneficially own these shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a significant but not controlling stake in Voyager Therapeutics, Inc. by Armistice Capital, LLC. The filing indicates a substantial investment without immediate aggressive action, suggesting a 'hold' or 'watchful waiting' stance.

Positives

• Armistice Capital, LLC, an investment manager, has taken a significant stake (5.58%) in Voyager Therapeutics, Inc., which could signal confidence in the company's future prospects.
• The filing indicates a substantial investment, potentially leading to increased liquidity or market interest in Voyager Therapeutics' stock.

Negatives

• The filing does not provide specific details on the investment strategy or future intentions of Armistice Capital beyond reporting ownership.
• The Master Fund disclaims beneficial ownership due to the investment management agreement, which might imply a separation of voting/dispositive power from direct beneficial ownership for the fund itself.

Risks

• Potential for increased market volatility if Armistice Capital decides to significantly alter its position.
• The investment is subject to the general risks associated with the biotechnology and pharmaceutical industry, including regulatory hurdles, clinical trial outcomes, and market competition.

Future Outlook

The filing itself does not contain forward-looking statements or specific guidance from Voyager Therapeutics, Inc. It solely reports the ownership stake of Armistice Capital, LLC.

Management Comments

• Armistice Capital, LLC exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that significant stake acquisitions by investment firms in biotechnology companies are common, often signaling a belief in the company's pipeline or strategic direction. Voyager Therapeutics operates in the gene therapy space, a highly competitive and capital-intensive sector.

Stakeholder Impact

• Shareholders: May see increased interest in the stock due to the significant stake held by a known investment manager, potentially influencing trading volume and price.
• Management of Voyager Therapeutics: Will need to consider the influence of a 5.58% shareholder in strategic decisions and corporate governance.

Next Steps

• Monitor future filings from Armistice Capital, LLC and Steven Boyd for any changes in their ownership stake or disclosed intentions.
• Observe Voyager Therapeutics, Inc.'s corporate actions and strategic announcements for potential impacts related to this significant shareholder.

Key Dates

Recommendation

The filing indicates a substantial investment by Armistice Capital, LLC, but it is a passive disclosure of ownership without any indication of activist intent or immediate strategic changes. This suggests a 'hold' position, awaiting further developments or strategic shifts from either the investor or the company.

Keywords

Voyager Therapeutics, Armistice Capital, Schedule 13G, Beneficial Ownership, Investment Management, Common Stock, Biotechnology